Rigosertib
Rigosertib (ON-01910 sodium salt, with Estybon as trade name) is a synthetic benzyl styryl sulfone in development by Onconova Therapeutics.[3] Rigosertib is in phase III clinical trials for the treatment of chronic myelomonocytic leukemia.[4]
![]() | |
Names | |
---|---|
IUPAC name
2‐[(2‐Methoxy‐5‐{[(E)‐2‐(2,4,6‐trimethoxyphenyl)ethenesulfonyl]methyl}phenyl)amino]acetic acid | |
Other names
ON-01910 | |
Identifiers | |
3D model (JSmol) |
|
ChEBI | |
ChEMBL | |
ChemSpider | |
KEGG | |
PubChem CID |
|
CompTox Dashboard (EPA) |
|
Properties | |
C21H25NO8S | |
Molar mass | 451.49 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
Infobox references | |
Its geometrical isomer (Z)-ON 01910·Na has less cytotoxicity on cancer cells.
Mechanism
Rigosertib is a microtubule-destabilizing agent.[5]
gollark: I do not think it's appropriate to be locked into maintenance from Tesla only.
gollark: Despite other cars possibly being unsafe if repaired wrong, they do not deliberately lock out repairs.
gollark: Also, it has waaaay too many degrees of freedom to predict things whatsoever.
gollark: I don't *actually* have particularly strong opinions on it because I don't know highly advanced physics things™, but apparently it's basically untestable.
gollark: Please get away from any children I might have in the future, proactively.
References
- "physical and chemical data on chemispider website".
- "physical and chemical data on chemispider website".
- "Onconova Therapeutics". Retrieved 2019-04-26.
- https://clinicaltrials.gov/ct2/show/NCT01928537
- Jost, M (2017). "Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent". Molecular Cell. 68 (1): 210–223.e6. doi:10.1016/j.molcel.2017.09.012. PMC 5640507. PMID 28985505. Retrieved 29 May 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.